Kinase inhibitor research is a comparatively recent branch of medicinal chemistry and
pharmacology and the first small‐molecule kinase inhibitor, imatinib, was approved for …

Selective small-molecule kinase inhibitors have emerged over the past decade as an
important class of anti-cancer agents, and have demonstrated impressive clinical efficacy in …

Small-molecule drug discovery for cancer therapy is making extraordinary progress within
the realm of advancing novel oncogenic protein kinase inhibitor lead compounds of …

The development of small molecule kinase drugs is a rapidly evolving field and represents
one of the most important research areas within oncology. This innovation letter provides an …

An increasing number of kinase inhibitor candidates are entering clinical development,
representing an important change in the pharmaceutical industry; notably, the development …

The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

Kinases have emerged as one of the most intensively pursued targets in current
pharmacological research, especially for cancer, due to their critical roles in cellular …

Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …

Great successes have been achieved in developing small-molecule kinase inhibitors as
anticancer therapeutic agents. However, kinase deregulation plays essential roles not only …

Highlights•Kinases constitute a very successful target area comprising now 28 approved
inhibitors.•Despite this success only few first in class kinase inhibitors entered clinical testing …